Journal article
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria
Diagnostic microbiology and infectious disease, Vol.70(3), pp.330-343
07/2011
DOI: 10.1016/j.diagmicrobio.2011.03.002
PMID: 21546199
Abstract
We reassessed the Clinical and Laboratory Standards Institute (CLSI) clinical breakpoints (CBPs) for voriconazole. We examined i) the essential (EA: ±2 dilutions) and categorical agreement between 24-h CLSI and EUCAST methods for voriconazole testing of Candida, ii) wild-type (WT) MICs and epidemiologic cutoff values (ECVs) for voriconazole by both CLSI and EUCAST methods, and iii) correlation of MICs with outcomes from previously published data using CLSI methods. We applied these findings to propose new 24-h species-specific CLSI CBPs. Adjusted 24-h CBPs for voriconazole and C. albicans, C. tropicalis, and C. parapsilosis (susceptible, ≤0.125 μg/mL; intermediate, 0.25–0.5 μg/mL; resistant, ≥1 μg/mL) should be more sensitive for detecting emerging resistance among common Candida species and provide consistency with EUCAST CBPs. In the absence of CBPs for voriconazole and C. glabrata (and less common species), we recommend that their respective ECVs be used to detect the emergence of non-WT strains.
Details
- Title: Subtitle
- Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria
- Creators
- Michael A Pfaller - University of Iowa Carver College of Medicine, Iowa City, IA 52246, USADavid Andes - University of Wisconsin, Madison, WI, USAMaiken C Arendrup - Statens Serum Institute, Copenhagen, DenmarkDaniel J Diekema - University of Iowa Carver College of Medicine, Iowa City, IA 52246, USAAna Espinel-Ingroff - VCU Medical Center, Richmond, VA, USABarbara D Alexander - Duke University, Durham, NC, USASteven D Brown - The Clinical Microbiology Institute, Wilsonville, OR, USAVishnu Chaturvedi - New York State Department of Health, Albany, NY, USACynthia L Fowler - bioMérieux, Inc., Durham, NC, USAMahmoud A Ghannoum - Case Western Reserve University, Cleveland, OH, USAElizabeth M Johnson - The HPA Centre for Infections, Kingsdown, Bristol, UKCynthia C Knapp - Trek Diagnostic Systems, Cleveland, OH, USAMary R Motyl - Merck and Company, Inc., Rahway, NJ, USALuis Ostrosky-Zeichner - University of Texas Medical School, Houston, TX, USAThomas J Walsh - Weil Cornell Medical College of Cornell University, New York, NY, USA
- Resource Type
- Journal article
- Publication Details
- Diagnostic microbiology and infectious disease, Vol.70(3), pp.330-343
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.diagmicrobio.2011.03.002
- PMID
- 21546199
- ISSN
- 0732-8893
- eISSN
- 1879-0070
- Grant note
- Pfizer
- Language
- English
- Date published
- 07/2011
- Academic Unit
- Infectious Diseases; Epidemiology; Pathology; Internal Medicine
- Record Identifier
- 9983986270602771
Metrics
26 Record Views